Department of Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Department of Psychiatry, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
PLoS One. 2023 Sep 21;18(9):e0291024. doi: 10.1371/journal.pone.0291024. eCollection 2023.
Cell division cycle associated 2 (CDCA2), a member of the cell division cycle associated proteins (CDCA) family, is crucial in the regulation of cell mitosis and DNA repair. CDCA2 was extensively examined in our work to determine its role in a wide range of cancers.
CDCA2 differential expression was studied in pan-cancer and in diverse molecular and immunological subgroups in this research. Additionally, the diagnostic and prognostic significance of CDCA2 in pan-cancer was also evaluated using receiver operating characteristic (ROC) and Kaplan-Meier (KM) curves. Prognostic value of CDCA2 in distinct clinical subgroups of lower grade glioma (LGG) was also investigated and a nomogram was constructed. Lastly, potential mechanisms of action of CDCA2 were interrogated including biological functions, ceRNA networks, m6A modification and immune infiltration.
CDCA2 is shown to be differentially expressed in a wide variety of cancers. Tumors are diagnosed and forecasted with a high degree of accuracy by CDCA2, and the quantity of expression CDCA2 is linked to the prognosis of many cancers. Additionally, the expression level of CDCA2 in various subgroups of LGG is also closely related to prognosis. The results of enrichment analyses reveal that CDCA2 is predominantly enriched in the cell cycle, mitosis, and DNA replication. Subsequently, hsa-miR-105-5p is predicted to target CDCA2. In addition, 4 lncRNAs were identified that may inhibit the hsa-miR-105-5p/CDCA2 axis in LGG. Meanwhile, CDCA2 expression is shown to be associated to m6A-related genes and levels of immune cell infiltration in LGG.
CDCA2 can serve as a novel biomarker for the diagnosis and prognosis in pan-cancer, especially in LGG. For the development of novel targeted therapies in LGG, it may be a potential molecular target. However, to be sure, we'll need to do additional biological experiments to back up our results from bioinformatic predictions.
细胞分裂周期相关蛋白 2(CDCA2)是细胞分裂周期相关蛋白(CDCA)家族的成员,在细胞有丝分裂和 DNA 修复的调控中起着至关重要的作用。在我们的研究中,广泛研究了 CDCA2 的作用,以确定其在多种癌症中的作用。
本研究中研究了泛癌和不同分子及免疫亚组中 CDCA2 的差异表达。此外,还使用接收器操作特征(ROC)和 Kaplan-Meier(KM)曲线评估了 CDCA2 在泛癌中的诊断和预后意义。还研究了 CDCA2 在低级别胶质瘤(LGG)不同临床亚组中的预后价值,并构建了列线图。最后,还研究了 CDCA2 的潜在作用机制,包括生物学功能、ceRNA 网络、m6A 修饰和免疫浸润。
CDCA2 在多种癌症中表现出差异表达。CDCA2 可高度准确地诊断和预测肿瘤,并且 CDCA2 的表达量与许多癌症的预后相关。此外,LGG 中不同亚组的 CDCA2 表达水平也与预后密切相关。富集分析结果表明,CDCA2 主要富集在细胞周期、有丝分裂和 DNA 复制中。随后,预测 hsa-miR-105-5p 可靶向 CDCA2。此外,还鉴定了 4 个 lncRNA 可能在 LGG 中抑制 hsa-miR-105-5p/CDCA2 轴。同时,CDCA2 的表达与 LGG 中的 m6A 相关基因和免疫细胞浸润水平相关。
CDCA2 可作为泛癌,尤其是 LGG 诊断和预后的新型生物标志物。对于 LGG 新型靶向治疗的开发,它可能是一个潜在的分子靶点。但是,为了确定,我们需要进行更多的生物实验来支持我们的生物信息学预测结果。